Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin

被引:10
作者
Isoda, Atsushi [1 ,2 ]
Miyazawa, Yuri [1 ]
Tahara, Kenichi [1 ]
Mihara, Masahiro [1 ]
Saito, Akio [1 ]
Matsumoto, Morio [1 ]
Sawamura, Morio [1 ]
机构
[1] Natl Hosp Org Shibukawa Med Ctr, Dept Hematol, Shibukawa, Gunma, Japan
[2] Hoshi Clin, Dept Hematol, Sapporo, Hokkaido, Japan
关键词
pure red cell aplasia; pembrolizumab; programed cell death 1; immune-related adverse events; direct anti-globulin test; intravenous immunoglobulin; AUTOIMMUNE HEMOLYTIC-ANEMIA; IMMUNOTHERAPY; RITUXIMAB; LYMPHOMA;
D O I
10.2169/internalmedicine.4467-20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We herein report a 64-year-old man who was treated with pembrolizumab for relapsed Hodgkin lymphoma. After the third administration of pembrolizumab, he showed acute anemia with a positive direct antiglobulin test. Because of the markedly erythroid hypoplasia, he was diagnosed with pure red cell aplasia (PRCA) caused by pembrolizumab. He was initially treated with prednisolone, but the reticulocytes decreased after tapering prednisolone. He then received high-dose intravenous immunoglobulin (WIG) with prednisolone, and PRCA was successfully treated. Although the pathogenesis of PRCA caused by immune checkpoint inhibitors (CPIs) remains unclear, WIG treatment may be effective for some steroid-refractory CPI-induced PRCA cases.
引用
收藏
页码:2041 / 2045
页数:5
相关论文
共 28 条
[1]   Primary Sjogren syndrome complicated by autoimmune hemolytic cell aplasia [J].
Assimakopoulos, Stelios F. ;
Michalopoulou, Sotiria ;
Melachrinou, Maria ;
Giannakoulas, Nikolaos ;
Papakonstantinou, Christos ;
Lekkou, Alexandra ;
Gogos, Charalambos .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 334 (06) :493-496
[2]  
BJORKHOLM M, 1993, J INTERN MED, V234, P119
[3]   IVIg treatment of pemphigus: How it works & how to use it [J].
Bystryn, JC ;
Rudolph, JL .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) :1093-1098
[4]   TREATMENT OF PURE RED-CELL APLASIA BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS [J].
CLAUVEL, JP ;
VAINCHENKER, W ;
HERRERA, A ;
DELLAGI, K ;
VINCI, G ;
TABILIO, A ;
LACOMBE, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1983, 55 (02) :380-382
[5]   Rituximab in the treatment of pembrolizumab-induced myasthenia gravis [J].
Crusz, S. M. ;
Radunovic, A. ;
Shepherd, S. ;
Shah, S. ;
Newey, V. ;
Phillips, M. ;
Lim, L. ;
Powles, T. ;
Szlosarek, P. W. ;
Shamash, J. ;
Rashid, S. .
EUROPEAN JOURNAL OF CANCER, 2018, 102 :49-51
[6]   Hematologic Complications of Immune Checkpoint Inhibitors [J].
Davis, Elizabeth J. ;
Salem, Joe-Elie ;
Young, Arissa ;
Green, Jennifer R. ;
Ferrell, P. Brent ;
Ancell, Kristin K. ;
Lebrun-Vignes, Benedicte ;
Moslehi, Javid J. ;
Johnson, Douglas B. .
ONCOLOGIST, 2019, 24 (05) :584-588
[7]  
Delaney N, 2019, LANCET HAEMATOL, V6, pE48, DOI [10.1016/S2352-3026(18)30175-3, 10.1016/52352-3026(18)30175-3]
[8]   Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab [J].
Gokozan, Hamza N. ;
Friedman, Judah D. ;
Schmaier, Alvin H. ;
Downes, Katharine A. ;
Farah, Lisa A. ;
Reeves, Hollie M. .
CLINICAL LUNG CANCER, 2019, 20 (05) :E560-E563
[9]   Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma [J].
Gordon, Ilyssa O. ;
Wade, Takisha ;
Chin, Kevin ;
Dickstein, Jerome ;
Gajewski, Thomas F. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) :1351-1353
[10]   Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors [J].
Handgretinger, R ;
Geiselhart, A ;
Moris, A ;
Grau, R ;
Teuffel, O ;
Bethge, W ;
Kanz, L ;
Fisch, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :278-284